Biotech | February 19, 2022
Tremfya achieves greater clinical responses in patients with ulcerative colitis
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
